Overview

PSD502 in Subjects With Premature Ejaculation

Status:
Active, not recruiting
Trial end date:
2021-06-30
Target enrollment:
Participant gender:
Summary
This study is being done to test the effect of PSD502 (the study medication) compared to placebo in subjects with premature ejaculation. PSD502 is a topical (applied to skin) anesthetic spray containing a mixture of two drugs called lidocaine and prilocaine that will be applied to the penis. Half of the subjects will receive PSD502 and half will receive placebo.
Phase:
Phase 2
Details
Lead Sponsor:
Plethora Solutions Ltd
Treatments:
EMLA
Lidocaine
Lidocaine, Prilocaine Drug Combination
Prilocaine